Full disclosure: your author has a dog. Both he and his family are deeply attached to her, as the pictures here attest. However, there are some things he will draw a line at. One of them is the increasing humanisation of animals. Not everyone would agree. The longevity trend we discussed last year (and initially in 2019) is now coming for your cat, dog and budgie.

The pet industry has been on a journey of both premiumisation and digitalisation for some time. Americans will likely spend a record-breaking $165bn on their pets this year, a 4.4% increase relative to 2025. Notably, Gen-Z pet-owners spend an average of $6,100 annually on their animals, versus the roughly $5,200 allocated by Millennials, or the much stingier $3,900 disbursed by members of Gen-X (your author falls into this latter category).

Where does all the money go? Food price inflation has hit the pet industry, but increasing sums are being spent on predictive and preventive healthcare solutions. Some of this is clearly because people want to enjoy more quality time with their pets. Equally important may be economics. One survey suggests that at least 50% of pet owners are actively researching ways to avoid emergency veterinary bills – which have a horrible tendency of being very expensive – through earlier intervention and prevention.

Do not be surprised, then, to see animals wearing biometrics monitors. DNA testing, gut microbiome and food sensitivity analytics, and multiple supplements all might form part of the pet longevity tool kit too. Another recent report suggests that some owners are using peptides in the hope of extending pet lifespans. Others are favouring rapamycin (an immunosuppressant thought to have anti-ageing properties) and even infra-red light therapy.

The prospect of longer life has always been a tantalising one, but it may be both naïve and hubristic to assume that we can defeat death. Something will kill you – and your animal – eventually. Natural selection has no interest in longevity per se. Further, we still don’t fully understand how or why the body ages. Neither we nor our pets may be getting any younger, but where we allocate our income still matters.

25 August 2026

The above is provided for information purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Any forward-looking statements are based on assumptions that may change. The views expressed are solely those of the author at the time of writing. This article should not be relied upon for investment decisions. Past performance does not predict future returns, the value of investments and income from them can fall as well as rise.

Photos by the author

Disclaimers

The document is provided for information purposes only and does not constitute investment advice or any recommendation to buy, or sell or otherwise transact in any investments. The document is not intended to be construed as investment research. The contents of this document are based upon sources of information which Heptagon Capital LLP believes to be reliable. However, except to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to the accuracy or completeness of this document or its contents and, Heptagon Capital LLP, its affiliate companies and its members, officers, employees, agents and advisors do not accept any liability or responsibility in respect of the information or any views expressed herein. Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation. Where this document provides forward-looking statements which are based on relevant reports, current opinions, expectations and projections, actual results could differ materially from those anticipated in such statements. All opinions and estimates included in the document are subject to change without notice and Heptagon Capital LLP is under no obligation to update or revise information contained in the document. Furthermore, Heptagon Capital LLP disclaims any liability for any loss, damage, costs or expenses (including direct, indirect, special and consequential) howsoever arising which any person may suffer or incur as a result of viewing or utilising any information included in this document. 

The document is protected by copyright. The use of any trademarks and logos displayed in the document without Heptagon Capital LLP’s prior written consent is strictly prohibited. Information in the document must not be published or redistributed without Heptagon Capital LLP’s prior written consent. 

Heptagon Capital LLP, 63 Brook Street, Mayfair, London W1K 4HS
tel +44 20 7070 1800
email [email protected] 

Partnership No: OC307355 Registered in England and Wales Authorised & Regulated by the Financial Conduct Authority 

Heptagon Capital Limited is licenced to conduct investment services by the Malta Financial Services Authority.

Featured Insights

  • Featured Insights

Heptagon Capital expands UCITS equity range with the launch of the Cornerstone Concentrated 30 US Equity Fund

  • Featured Insights

View From The Top: Renormalisation

  • Featured Insights

Season 8, Post 35: Just scratching the surface

Receive the updates

Sign up to our monthly email newsletter for the latest fund updates, webcasts and insights.